TRAILing death in cancer

Molecular Aspects of Medicine

Volumn 31, Issue 1, 2010, Pages 93-112

  Mellier, Gregory ^a   Huang, Sinong ^a   Shenoy, Kirthan ^a   Pervaiz, Shazib ^a,b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d SINGAPORE MIT ALLIANCE   (Singapore)

Author keywords

Apoptosis; Chemo sensitization; Death receptors; Mitochondria; TRAIL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANDROGRAPHOLIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CURCUMIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEHYDRODIDEMNIN B; FLAVOPIRIDOL; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY 303511; MITOGEN ACTIVATED PROTEIN KINASE; MYRICETIN; NYSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL; PROTEIN BCL 2; QUERCETIN DERIVATIVE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RESVERATROL; ROSIGLITAZONE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SILIBININ; TROGLITAZONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHAFERIN A; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CELL SURFACE; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGOMERIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UPREGULATION;

ANIMALS; APOPTOSIS; HUMANS; MITOCHONDRIA; NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77649190268     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2009.12.002     Document Type: Review

References (210)

1. Arbour N., Rastikerdar E., McCrea E., Lapierre Y., Dorr J., Bar-Or A., and Antel J.P. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult. Scler. 11 6 (2005) 652-657
2. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 2 (1999) 155-162
3. Ashkenazi A., Holland P., and Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26 21 (2008) 3621-3630
4. Belyanskaya L.L., Ziogas A., Hopkins-Donaldson S., Kurtz S., Simon H.U., Stahel R., and Zangemeister-Wittke U. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 60 3 (2008) 355-365
5. Bernard D., Quatannens B., Vandenbunder B., and Abbadie C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J. Biol. Chem. 276 29 (2001) 27322-27328
6. Bin L., Thorburn J., Thomas L.R., Clark P.E., Humphreys R., and Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J. Biol. Chem. 282 38 (2007) 28189-28194
7. Bonavida B., Ng C.P., Jazirehi A., Schiller G., and Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int. J. Oncol. 15 4 (1999) 793-802
8. Cha S.S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C., Sung Y.C., and Oh B.H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11 2 (1999) 253-261
9. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11 8 (2004) 915-923
10. Chen L.H., Jiang C.C., Kiejda K.A., Wang Y.F., Thorne R.F., Zhang X.D., and Hersey P. Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis 28 11 (2007) 2328-2336
11. Chen J.J., Chou C.W., Chang Y.F., and Chen C.C. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J. Immunol. 180 12 (2008) 8030-8039
12. Cheng, E.H., Wei, M.C., Weiler, S., Flavell, R.A., Mak, T.W., Lindsten, T., Korsmeyer, S.J., 2001. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8(3), 705-711.
13. Cheng J., Hylander B.L., Baer M.R., Chen X., and Repasky E.A. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol. Cancer Ther. 5 7 (2006) 1844-1853
14. Choi B.K., Choi C.H., Oh H.L., and Kim Y.K. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology 25 6 (2004) 915-924
15. Clayer M., Bouralexis S., Evdokiou A., Hay S., Atkins G.J., and Findlay D.M. Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J. Orthop. Surg. (Hong Kong) 9 2 (2001) 19-22
16. Connolly K., Mitter R., Muir M., Jodrell D., and Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother. Pharmacol. 64 2 (2009) 307-316
17. Cremesti, A.E., Goni, F.M., Kolesnick, R., 2002. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett. 531(1), 47-53.
18. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 3 (2002) 1356-1361
19. Dalen H., and Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br. J. Cancer 88 1 (2003) 153-158
20. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 2 (2004) 205-219
21. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., Xu X.N., Jin B.Q., Pezzella F., and Screaton G.R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 15 6 (2005) 430-438
22. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 6 (1997) 813-820
23. Delmas D., Rebe C., Micheau O., Athias A., Gambert P., Grazide S., Laurent G., Latruffe N., and Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 55 (2004) 8979-8986
24. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16 1 (2002) 33-45
25. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., Morici L.A., Lenz L.L., Cado D., Riley L.W., and Winoto A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21 6 (2004) 877-889
26. Djerbi M., Darreh-Shori T., Zhivotovsky B., and Grandien A. Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. Scand. J. Immunol. 54 1-2 (2001) 180-189
27. Dolcet X., Llobet D., Pallares J., Rue M., Comella J.X., and Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest. 85 7 (2005) 885-894
28. Earel Jr. J.K., VanOosten R.L., and Griffith T.S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66 1 (2006) 499-507
29. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 25 (2003) 3842-3852
30. Ehrlich S., Infante-Duarte C., Seeger B., and Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24 6 (2003) 244-253
31. Elrod H.A., and Sun S.Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther. 7 2 (2008) 163-173
32. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 23 (1998) 14363-14367
33. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., and Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 113 8 (2009) 1710-1722
34. Falschlehner C., Emmerich C.H., Gerlach B., and Walczak H. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 7-8 (2007) 1462-1475
35. Finnberg N., Gruber J.J., Fei P., Rudolph D., Bric A., Kim S.H., Burns T.F., Ajuha H., Page R., Wu G.S., Chen Y., McKenna W.G., Bernhard E., Lowe S., Mak T., and El-Deiry W.S. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol. Cell Biol. 25 5 (2005) 2000-2013
36. Fisher M.J., Virmani A.K., Wu L., Aplenc R., Harper J.C., Powell S.M., Rebbeck T.R., Sidransky D., Gazdar A.F., and El-Deiry W.S. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7 6 (2001) 1688-1697
37. Gajate, C., Mollinedo, F., 2005. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 280(12), 11641-11647.
38. Galluzzi L., Maiuri M.C., Vitale I., Zischka H., Castedo M., Zitvogel L., and Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 14 7 (2007) 1237-1243
39. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Buchler P., Haas T.L., Schader M.B., Untergasser A., Stremmel W., and Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. 12 8 (2006) 2640-2646
40. Geserick P., Drewniok C., Hupe M., Haas T.L., Diessenbacher P., Sprick M.R., Schon M.P., Henkler F., Gollnick H., Walczak H., and Leverkus M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27 22 (2008) 3211-3220
41. Gibson S.B., Oyer R., Spalding A.C., Anderson S.M., and Johnson G.L. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell Biol. 20 1 (2000) 205-212
42. Gill C., Dowling C., O'Neill A.J., and Watson R.W. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol. Cancer 8 (2009) 39
43. Golks A., Brenner D., Fritsch C., Krammer P.H., and Lavrik I.N. C-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 280 15 (2005) 14507-14513
44. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161 6 (1998) 2833-2840
45. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., Smith C.A., Goodwin R.G., and Kubin M.Z. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162 5 (1999) 2597-2605
46. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., Schutz G., Greiner E.F., Kemp C.J., and Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 118 1 (2008) 100-110
47. Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., O'Bryan E., Fumero C., Wang H.G., and Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99 9 (2002) 3419-3426
48. Guseva N.V., Rokhlin O.W., Taghiyev A.F., and Cohen M.B. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). Breast Cancer Res. Treat. 107 3 (2008) 349-357
49. Halaas O., Vik R., Ashkenazi A., and Espevik T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand. J. Immunol. 51 3 (2000) 244-250
50. Hao J.H., Yu M., Liu F.T., Newland A.C., and Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 64 10 (2004) 3607-3616
51. Harper N., Farrow S.N., Kaptein A., Cohen G.M., and MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 276 37 (2001) 34743-34752
52. Herbst, R.S., 2006. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol. 24.
53. Hetschko H., Voss V., Seifert V., Prehn J.H., and Kogel D. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J. 275 8 (2008) 1925-1936
54. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., Zangemeister-Wittke U., and Stahel R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10 3 (2003) 356-364
55. Horak P., Pils D., Haller G., Pribill I., Roessler M., Tomek S., Horvat R., Zeillinger R., Zielinski C., and Krainer M. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. 3 6 (2005) 335-343
56. Horak, P., Pils, D., Kaider, A., Pinter, A., Elandt, K., Sax, C., Zielinski, C.C., Horvat, R., Zeillinger, R., Reinthaller, A., Krainer, M., 2005. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin. Cancer. Res. 11(24 Pt 1), 8585-8591.
57. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Nakanishi R., Nishino H., Matsui H., and Sakai T. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24 48 (2005) 7180-7189
58. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., and Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 5 4 (2006) 945-951
59. Hu S., Vincenz C., Ni J., Gentz R., and Dixit V.M. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272 28 (1997) 17255-17257
60. Huang S., and Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 68 8 (2008) 2944-2951
61. Hymowitz S.G., O'Connell M.P., Ultsch M.H., Hurst A., Totpal K., Ashkenazi A., de Vos A.M., and Kelley R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39 4 (2000) 633-640
62. Inoue T., Shiraki K., Fuke H., Yamanaka Y., Miyashita K., Yamaguchi Y., Yamamoto N., Ito K., Sugimoto K., and Nakano T. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 17 3 (2006) 261-268
63. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., and Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 388 6638 (1997) 190-195
64. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 2 (2005) 139-163
65. Jin Z., McDonald E.R., Dicker D.T., and El-Deiry W.S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279 34 (2004) 35829-35839
66. Jin C.Y., Moon D.O., Lee J.D., Heo M.S., Choi Y.H., Lee C.M., Park Y.M., and Kim G.Y. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis 28 5 (2007) 1058-1066
67. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 5 (2000) 564-567
68. Joy A.M., Beaudry C.E., Tran N.L., Ponce F.A., Holz D.R., Demuth T., and Berens M.E. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J. Cell Sci. 116 Pt 21 (2003) 4409-4417
69. Jung E.M., Lim J.H., Lee T.J., Park J.W., Choi K.S., and Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26 11 (2005) 1905-1913
70. Jung E.M., Park J.W., Choi K.S., Lee H.I., Lee K.S., and Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 27 10 (2006) 2008-2017
71. Kandasamy K., and Kraft A.S. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol. Cancer Ther. 7 5 (2008) 1091-1100
72. Kandasamy K., Srinivasula S.M., Alnemri E.S., Thompson C.B., Korsmeyer S.J., Bryant J.L., and Srivastava R.K. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 63 7 (2003) 1712-1721
73. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 9 (1999) 1451-1460
74. Kayagaki N., Yamaguchi N., Nakayama M., Kawasaki A., Akiba H., Okumura K., and Yagita H. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162 5 (1999) 2639-2647
75. Kemp T.J., Elzey B.D., and Griffith T.S. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171 1 (2003) 212-218
76. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., Logsdon C.D., Abbruzzese J.L., and McConkey D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5 9 (2006) 2251-2260
77. Kim E.H., Kim S.U., Shin D.Y., and Choi K.S. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23 2 (2004) 446-456
78. Kim Y.K., Kim H.J., Kwon C.H., Kim J.H., Woo J.S., Jung J.S., and Kim J.M. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol. 25 5 (2005) 374-382
79. Kim E.H., Kim S.U., and Choi K.S. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24 5 (2005) 838-849
80. Kim E.H., Kim H.S., Kim S.U., Noh E.J., Lee J.S., and Choi K.S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24 46 (2005) 6877-6889
81. Kim H., Kim E.H., Eom Y.W., Kim W.H., Kwon T.K., Lee S.J., and Choi K.S. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 66 3 (2006) 1740-1750
82. Kim S.H., Ricci M.S., and El-Deiry W.S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 68 7 (2008) 2062-2064
83. Kim Y.H., Jung E.M., Lee T.J., Kim S.H., Choi Y.H., Park J.W., Choi K.S., and Kwon T.K. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 44 6 (2008) 1055-1068
84. Kim E.H., Yoon M.J., Kim S.U., Kwon T.K., Sohn S., and Choi K.S. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res. 68 1 (2008) 266-275
85. Kim J.Y., Kim E.H., Park S.S., Lim J.H., Kwon T.K., and Choi K.S. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J. Cell Biochem. 105 6 (2008) 1386-1398
86. Kimberley F.C., and Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14 5 (2004) 359-372
87. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., and Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14 22 (1995) 5579-5588
88. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 6 (2000) 611-620
89. Koschny R., Holland H., Sykora J., Haas T.L., Sprick M.R., Ganten T.M., Krupp W., Bauer M., Ahnert P., Meixensberger J., and Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 13 11 (2007) 3403-3412
90. Koschny, R., Walczak, H., Ganten, T.M., 2007. The promise of TRAIL -- potential and risks of a novel anticancer therapy. J. Mol. Med. 85(9), 923-935.
91. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., and Dimanche-Boitrel M.T. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22 12 (2003) 1807-1816
92. Larribere L., Khaled M., Tartare-Deckert S., Busca R., Luciano F., Bille K., Valony G., Eychene A., Auberger P., Ortonne J.P., Ballotti R., and Bertolotto C. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ. 11 10 (2004) 1084-1091
93. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 4 (2001) 383-385
94. LeBlanc, H.N., Ashkenazi, A., 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10(1), 66-75.
95. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., and Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8 3 (2002) 274-281
96. Lee T.J., Um H.J., Min do S., Park J.W., Choi K.S., and Kwon T.K. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 46 12 (2009) 1639-1649
97. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y., Lee J.H., Han S.Y., Park J.Y., Oh R.R., Jang J.J., Han J.Y., Lee J.Y., and Yoo N.J. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59 22 (1999) 5683-5686
98. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y., Lee J.H., Han S.Y., Park J.Y., Oh R.R., Kang C.S., Kim K.M., Jang J.J., Nam S.W., Lee J.Y., and Yoo N.J. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20 3 (2001) 399-403
99. Lee K.Y., Park J.S., Jee Y.K., and Rosen G.D. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp. Mol. Med. 34 6 (2002) 462-468
100. Lee T.J., Jung E.M., Lee J.T., Kim S., Park J.W., Choi K.S., and Kwon T.K. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol. Cancer Ther. 5 11 (2006) 2737-2746
101. Lee T.J., Lee J.T., Park J.W., and Kwon T.K. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351 4 (2006) 1024-1030
102. Li H., and Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41 1 (2008) 1-8
103. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., and Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 5689 (2004) 1471-1474
104. Li H., Wang X., Li N., Qiu J., Zhang Y., and Cao X. HPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J. Biol. Chem. 282 7 (2007) 4943-4950
105. Ling, J., 2006. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J. Clin. Oncol. 24.
106. Lippa M.S., Strockbine L.D., Le T.T., Branstetter D.G., Strathdee C.A., and Holland P.M. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 12 8 (2007) 1465-1478
107. Liu S., Yu Y., Zhang M., Wang W., and Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol. 166 9 (2001) 5407-5415
108. Liu Q., Hilsenbeck S., and Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 10 (2003) 4078-4087
109. Liu X., Yue P., Chen S., Hu L., Lonial S., Khuri F.R., and Sun S.Y. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 67 10 (2007) 4981-4988
110. Liu F.T., Agrawal S.G., Gribben J.G., Ye H., Du M.Q., Newland A.C., and Jia L. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111 5 (2008) 2797-2805
111. MacFarlane, M., Harper, N., Snowden, R.T., Dyer, M.J., Barnett, G.A., Pringle, J.H., Cohen, G.M., 2002. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21(44), 6809-6818.
112. Mahalingam, D., Szegezdi, E., Keane, M., Jong, S., Samali, A., 2002. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 35(3), 280-288.
113. Malhi H., and Gores G.J. TRAIL resistance results in cancer progression: a TRAIL to perdition?. Oncogene 25 56 (2007) 7333-7335
114. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., and Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 12 (1997) 1003-1006
115. Martin, S., Phillips, D.C., Szekely-Szucs, K., Elghazi, L., Desmots, F., Houghton, J.A., 2005. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res. 65(24), 11447-11458.
116. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., and Peter M.E. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16 10 (1997) 2794-2804
117. Mendoza F.J., Ishdorj G., Hu X., and Gibson S.B. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 13 6 (2008) 756-770
118. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., and Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282 41 (2007) 29831-29846
119. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., and Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 26 19 (2006) 7046-7055
120. Micheau O., Lens S., Gaide O., Alevizopoulos K., and Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell Biol. 21 16 (2001) 5299-5305
121. Mori T., Doi R., Kida A., Nagai K., Kami K., Ito D., Toyoda E., Kawaguchi Y., and Uemoto S. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J. Surg. Res. 142 2 (2007) 281-286
122. Mucha S.R., Rizzani A., Gerbes A.L., Camaj P., Thasler W.E., Bruns C.J., Eichhorst S.T., Gallmeier E., Kolligs F.T., Goke B., and De Toni E.N. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut 58 5 (2009) 688-698
123. Muhlethaler-Mottet A., Flahaut M., Bourloud K.B., Auderset K., Meier R., Joseph J.M., and Gross N. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 6 (2006) 214
124. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62 20 (2002) 5800-5806
125. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., and Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23 37 (2004) 6261-6271
126. Nakata, S., Yoshida, T., Shiraishi, T., Horinaka, M., Kouhara, J., Wakada, M., Sakai, T., 2006. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol. Cancer Ther. 5(7), 1827-1835.
127. Nakshatri H., Rice S.E., and Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23 44 (2004) 7330-7344
128. Ndozangue-Touriguine O., Sebbagh M., Merino D., Micheau O., Bertoglio J., and Breard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27 46 (2008) 6012-6022
129. Ng C.P., and Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 1 12 (2002) 1051-1058
130. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., and Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61 2 (2001) 759-763
131. Ortiz-Ferron G., Yerbes R., Eramo A., and Lopez-Perez A.I. De Maria, R., Lopez-Rivas, A., Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res. 18 6 (2008) 664-676
132. Ozoren N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4 6 (2002) 551-557
133. Pai S.I., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D., and El-Deiry W.S. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 58 16 (1998) 3513-3518
134. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 5309 (1997) 111-113
135. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 5327 (1997) 815-818
136. Panner A., James C.D., Berger M.S., and Pieper R.O. MTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25 20 (2005) 8809-8823
137. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 22 (1996) 12687-12690
138. Poh T.W., and Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65 14 (2005) 6264-6274
139. Poh T.W., Huang S., Hirpara J.L., and Pervaiz S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ. 14 10 (2007) 1813-1825
140. Psahoulia F.H., Drosopoulos K.G., Doubravska L., Andera L., and Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 6 9 (2007) 2591-2599
141. Ravi R., and Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 62 6 (2002) 1583-1587
142. Ray S., Bucur O., and Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10 6 (2005) 1411-1418
143. Romagnoli M., Desplanques G., Maiga S., Legouill S., Dreano M., Bataille R., and Barille-Nion S. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res. 13 20 (2007) 6010-6018
144. Rosato R.R., Almenara J.A., Coe S., and Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67 19 (2007) 9490-9500
145. Rossin, A., Derouet, M., Abdel-Sater, F., Hueber, A.O., 2009. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem. J. 419(1), 185-192, 2p. following 192.
146. Safa A.R., Day T.W., and Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8 1 (2008) 37-46
147. Sayers T.J., and Murphy W.J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. 55 1 (2006) 76-84
148. Schneider P., Olson D., Tardivel A., Browning B., Lugovskoy A., Gong D., Dobles M., Hertig S., Hofmann K., Van Vlijmen H., Hsu Y.M., Burkly L.C., Tschopp J., and Zheng T.S. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 278 7 (2003) 5444-5454
149. Schultze K., Bock B., Eckert A., Oevermann L., Ramacher D., Wiestler O., and Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11 9 (2006) 1503-1512
150. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 17 (2003) 2250-2256
151. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., Forti G., Capitani S., and Zauli G. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol. Life Sci. 61 15 (2004) 1965-1974
152. Sedger L.M., Glaccum M.B., Schuh J.C., Kanaly S.T., Williamson E., Kayagaki N., Yun T., Smolak P., Le T., Goodwin R., and Gliniak B. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32 8 (2002) 2246-2254
153. Shankar S., Ganapathy S., Chen Q., and Srivastava R.K. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer 7 (2008) 16
154. Shenoy K., Wu Y., and Pervaiz S. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 69 5 (2009) 1941-1950
155. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 5327 (1997) 818-821
156. Shetty S., Gladden J.B., Henson E.S., Hu X., Villanueva J., Haney N., and Gibson S.B. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 7 5 (2002) 413-420
157. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., Lee J.H., Lee S.K., Lee S.N., Jung S.S., Han J.Y., Kim H., Lee J.Y., and Yoo N.J. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61 13 (2001) 4942-4946
158. Shrader M., Pino M.S., Lashinger L., Bar-Eli M., Adam L., Dinney C.P., and McConkey D.J. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67 4 (2007) 1430-1435
159. Siegelin M.D., Reuss D.E., Habel A., Herold-Mende C., and Von Deimling A. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Mol. Cancer Ther. 7 11 (2008) 3566-3574
160. Siegelin M.D., Gaiser T., and Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem. Int. 55 6 (2009) 423-430
161. Siegelin M.D., Gaiser T., Habel A., and Siegelin Y. Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. Neurosci. Lett. 454 3 (2009) 223-228
162. Siegelin M.D., Gaiser T., Habel A., and Siegelin Y. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett. 283 2 (2009) 230-238
163. Siegelin M.D., Reuss D.E., Habel A., Rami A., and Von Deimling A. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol. 11 2 (2009) 122-131
164. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 17 (2003) 5390-5400
165. Singh T.R., Shankar S., and Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24 29 (2005) 4609-4623
166. Sinicrope F.A., Penington R.C., and Tang X.M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 10 24 (2004) 8284-8292
167. Soderstrom T.S., Poukkula M., Holmstrom T.H., Heiskanen K.M., and Eriksson J.E. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169 6 (2002) 2851-2860
168. Son Y.G., Kim E.H., Kim J.Y., Kim S.U., Kwon T.K., Yoon A.R., Yun C.O., and Choi K.S. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res. 67 17 (2007) 8274-8284
169. Song K., Benhaga N., Anderson R.L., and Khosravi-Far R. Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res. 66 12 (2006) 6304-6311
170. Song J.J., An J.Y., Kwon Y.T., and Lee Y.J. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J. Biol. Chem. 282 1 (2007) 319-328
171. Su R.Y., Chi K.H., Huang D.Y., Tai M.H., and Lin W.W. 15-deoxy-Delta12, 14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol. Cancer Ther. 7 10 (2008) 3429-3440
172. Sun S.Y., Yue P., Zhou J.Y., Wang Y., Choi Kim H.R., Lotan R., and Wu G.S. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem. Biophys. Res. Commun. 280 3 (2001) 788-797
173. Symanowski J., Vogelzang N., Zawel L., Atadja P., Pass H., and Sharma S. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J. Thorac. Oncol. 4 2 (2009) 149-160
174. Szegezdi E., Cahill S., Meyer M., O'Dwyer M., and Samali A. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br. J. Cancer 94 3 (2006) 398-406
175. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Yamaguchi N., Yagita H., and Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 214 2 (2001) 194-200
176. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., and Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195 2 (2002) 161-169
177. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 298 3 (2001) 865-872
178. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., and Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64 10 (2004) 3517-3524
179. Teraishi F., Kagawa S., Watanabe T., Tango Y., Kawashima T., Umeoka T., Nisizaki M., Tanaka N., and Fujiwara T. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett. 579 19 (2005) 4069-4075
180. Thayaparasingham B., Kunz A., Peters N., and Kulms D. Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. Oncogene 28 3 (2009) 345-362
181. Thorpe J.A., Christian P.A., and Schwarze S.R. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 68 2 (2008) 200-209
182. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., and Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276 19 (2001) 16484-16490
183. Van Geelen C.M., De Vries E.G., and de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 7 6 (2004) 345-358
184. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., and Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 49 (2005) 40599-40608
185. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Gschwend J.E., Simmet T., Debatin K.M., and Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 68 19 (2008) 7956-7965
186. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Bhanot U., Hasel C., Moller P., Gschwend J.E., Simmet T., Debatin K.M., and Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 69 6 (2009) 2425-2434
187. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., Von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 9 (2007) 1070-1077
188. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 2 (1999) 157-163
189. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27 48 (2008) 6207-6215
190. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., and Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer. Ther. 7 5 (2008) 1156-1163
191. Wang C., Chen T., Zhang N., Yang M., Li B., Lu X., Cao X., and Ling C. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J. Biol. Chem. 284 6 (2009) 3804-3813
192. Waterhouse N.J., Ricci J.E., and Green D.R. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 84 2-3 (2002) 113-121
193. Wen J., Ramadevi N., Nguyen D., Perkins C., Worthington E., and Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96 12 (2000) 3900-3906
194. Wenger T., Mattern J., Penzel R., Gassler N., Haas T.L., Sprick M.R., Walczak H., Krammer P.H., Debatin K.M., and Herr I. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ. 13 10 (2006) 1740-1751
195. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 6 (1995) 673-682
196. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., and El-Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59 12 (1999) 2770-2775
197. Yeow W.S., Baras A., Chua A., Nguyen D.M., Sehgal S.S., and Schrump D.S. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Thorac. Cardiovasc. Surg. 132 6 (2006) 1356-1362
198. Yoshida T., Shiraishi T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., and Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 65 13 (2005) 5662-5667
199. Yue H.H., Diehl G.E., and Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 12 1 (2005) 94-97
200. Zauli G., Sancilio S., Cataldi A., Sabatini N., Bosco D., and Di Pietro R. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J. Cell Physiol. 202 3 (2005) 900-911
201. Zerafa N., Westwood J.A., Cretney E., Mitchell S., Waring P., Iezzi M., and Smyth M.J. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175 9 (2005) 5586-5590
202. Zhang L., and Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12 3 (2005) 228-237
203. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., and Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59 11 (1999) 2747-2753
204. Zhang X.D., Zhang X.Y., Gray C.P., Nguyen T., and Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61 19 (2001) 7339-7348
205. Zhang L., Zhu H., Teraishi F., Davis J.J., Guo W., Fan Z., and Fang B. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7 6 (2005) 594-602
206. Zheng S.J., Jiang J., Shen H., and Chen Y.H. Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. J. Immunol. 173 9 (2004) 5652-5658
207. Zhou J., Lu G.D., Ong C.S., Ong C.N., and Shen H.M. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol. Cancer Ther. 7 7 (2008) 2170-2180
208. Zhuang S., and Schnellmann R.G. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319 3 (2006) 991-997
209. Zou H., Henzel W.J., Liu X., Lutschg A., and Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90 3 (1997) 405-413
210. Zou W., Liu X., Yue P., Zhou Z., Sporn M.B., Lotan R., Khuri F.R., and Sun S.Y. C-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64 20 (2004) 7570-7578